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Development of a simple enzyme-linked immunosorbent assay for 
quantitative estimation of aflatoxin B1 albumin adduct in humans 
 
Aflatoxin B1 (AFB1), a hepatotoxicant 
and hepatocarcinogenic secondary meta-
bolite of Aspergillus flavus and Aspergil-
lus parasiticus, is a frequent contaminant 
in several foods (e.g. groundnut, maize, 
chillies, etc.)1. Human exposure to AFB1 
occurs through dietary intake of aflatoxin-
contaminated food2. AFB1 heightens the 
risk of liver cirrhosis and hepatocellular 
carcinoma (HCC)3, particularly in indi-
viduals affected with hepatitis B virus 
(HBV) due to synergistic interaction  
between AFB1 and HBV in the causation 
of HCC4. Identification of aflatoxin-
exposed individuals would facilitate  
introduction of preventive interventions 
to reduce the risk of liver disorders and 
HCC3. Various measures that reduce 
fungal infestation and toxin contamina-
tion in foods are being enforced to pre-
vent human exposure to aflatoxins2. 
Some of them involve assessment of 
aflatoxin exposure in humans to identify 
high-risk communities or individuals to 
facilitate HCC preventive interventions3. 
 Based on the knowledge of AFB1  
metabolism in humans, biomarkers in the 
blood, urine, faeces and tissue have been 
identified that have been used as a proxy 
to monitor AFB1 exposure in humans5. 
The AFB1-8-9-epoxide lysine (AFB1-lys) 
adduct found in human serum albumin 
(HSA) is a widely used AFB1 biomarker 
as it reflects actual dose resulting from 
aflatoxin exposure over a period of 2–3 
months6,7. Various techniques based on 
mass spectrometry, high-performance 
liquid chromatography (HPLC) and  
enzyme-linked immunosorbent assay 
(ELISA) have been used to monitor 
AFB1-lys7,8. In the present study, we 
have produced high titred polyclonal an-
tibodies against synthetic AFB1-lys and 
developed a simple indirect competitive 
(IC)-ELISA for quantitative estimation 
of AFB1-lys adducts in HSA. 
 Unless specified, all the reagents used 
in the study were procured from Sigma–
Aldrich, USA. Three AFB1-8,9-epoxide 
conjugates, AFB1-lys, AFB1-ovalbumin 
(AFB1-ova) and AFB1-bovine serum  
albumin (AFB1-BSA), were synthesized 
as described before9,10, except that  
biphasic reactions were incubated over-
night (~ 14 h). AFB1-lys and AFB1-ova 
were used as reference standard and 
coating conjugate respectively, in IC-
ELISA; whereas AFB1-BSA was used as 
an immunogen to produce antiserum in a 
New Zealand White inbred rabbit. Im-
munization via intramuscular injections 
was performed using 250 μg AFB1-BSA 
in 250 μl of 0.1 M phosphate buffer, pH 
7.2, emulsified with an equal volume of 
Freund’s complete adjuvant. Four subse-
quent injections were given at weekly in-
tervals using AFB1-BSA emulsified in 
equal volumes of Freund’s incomplete 
adjuvant. The rabbit was bled for poly-
clonal antiserum a week after the last  
injection for four weeks at weekly inter-
vals. Subsequently, a booster immuniza-
tion was given with AFB1-BSA 
emulsified in incomplete Freund’s adju-
vant. After two weeks of rest, the animal 
was bleed for polyclonal antiserum at 
weekly intervals for eight weeks. 
 The titre of each bleed of antiserum 
was determined by IC-ELISA performed 
in 96-well microtitre plates (Nunc®  
MaxiSorp, Sigma–Aldrich)11,12. Prior to 
utilizing this procedure, optimum con-
centrations of the AFB1-lys and AFB1-
ova; antiserum and alkaline phosphatase 
(ALP)-labelled anti-rabbit IgG conjugate 
were determined. Wells of the ELISA 
plates were coated with 150 μl of 
10 ng/ml AFB1-ova in 0.2 M carbonate 
coating buffer, pH 9.6, and incubated 
overnight at 4°C. The wells were re-
placed with 0.2% BSA in PBS containing 
0.05% Tween-20 (PBST) to block free 
sites of the well. In each subsequent step, 
plates were incubated at 37°C for 1 h fol-
lowed by three washes with PBST. Hun-
dred microlitres of AFB1-lys standards 
ranging from 7.8 to 2000 pg/ml PBST 
were added in duplicate wells and they 
were supplemented with 50 μl of 
1 : 40,000 (v/v) AFB1-lys antiserum in 
PBST containing 1.5% BSA (PBST–
BSA). Sample wells constituted the 
same, except, instead of the standard, 
20 μl of 1 : 5 (v/v) hydrolysed albumin 
(described below) was added. This was 
followed by addition of 150 μl of ALP-
labelled anti-rabbit IgG at 1 : 2000 in 
PBST–BSA. In the final step, 1 mg/ml 
para-nitrophenyl phosphate in 10%  
diethanolamine buffer, pH 9.8, was 
added and the plates were incubated at 
37°C for 1–3 h. Optical densities (OD) 
were read in an ELISA plate reader 
(Multiskan Plus, Labsystems) fitted with 
a 405 nm filter. Recordings were taken 
till OD values of the control well reached 
1.5 ± 2.0 OD. The toxin concentration 
was calculated using SigmaPlot version 
2.01, and the formula (A × D × E)/ 
G pg/mg albumin, where A is the concen-
tration of AFB1-lys (pg/ml), D the dilu-
tion factor (ml), E the extraction solvent 
volume (ml) and G the sample weight 
(mg). 
 The procedures used in the present 
study have contributed to the production 
of high titred and specific antiserum 
against AFB1-lys, and high yields 
(55.5 μg/μl) of synthetic AFB1 adduct. 
Titre of the antiserum prior to booster 
 
 
Figure 1. Evaluation of polyclonal antibodies (1 : 40,000 v/v) against AFB1-lys, BSA and 
ovalbumin in IC-ELISA. 
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Table 1. Percentage recovery of AFB1-lys from spiked human serum albumin by IC-ELISA 
 Estimated by IC-ELISA (pg/mg) Recovery* (%) 
 
Sample no. AFB1-lys spiked in HSA (pg) Exp. 1 Exp. 2 Exp. 1 Exp. 2 SD (±) 
 
1 2000 1677 1832 83.8 91.6 5.5 
2 1000 1049 979 104.9 97.9 4.9 
3  500 556 483 111.2 96.6 10.3 
4  200 189 212 94.5 106 8.1 
5   50 51.38 52.85 102.7 105.7 2.1 
*(Concentration estimated by IC-ELISA/amount of AFB1-lys spiked) × 100. 
 
 
Table 2. Quantitative estimation of AFB1-lys in human serum albumin by HPLC and in HPLC fraction  
 by IC-ELISA 
 Concentration of AFB1-lys (pg/mg) 
    Recovery of AFB1-lys in 
Sample no. HPLC IC-ELISA HPLC fraction by IC-ELISA (%) 
 
1a 72 69.53 96.5 (± 1.7) 
1b 72 67.2 93 (± 3.4) 
2b 109.08 103 94.2 (± 4.3) 
3b 101 75.82 75.0 (± 17.8) 
4c 0d –d – 
aHydrolysed sample purified with Sep-Pak cartridge. bHydrolysed sample purified by ethanol precipita-
tion. cNegative control. dNo peak in HPLC and OD equivalent to negative control in ELISA. 
 
 
 
 
Figure 2. Reversed phase HPLC of proteinase-K hydrolysed human serum albumin spiked with AFB1-lys. 
 
 
immunization was between 1 : 2000 to 
1 : 10,000; and titre of the antiserum 
post-booster injection was 1 : 40,000 to 
1 : 75,000, suggesting positive effect of 
longer resting time and booster dose on 
improving the antiserum titre. The opti-
mum antiserum dilution for sensitive de-
tection of AFB1-lys was determined by 
50% displacement values of B/B0, where 
B is the OD of the AFB1-lys, and B0 the 
OD of the negative control (Figure 1). 
This has identified 1 : 40,000 (v/v) as the 
optimum antiserum dilution for the de-
tection of up to 5 pg AFB1/mg HSA. 
 To determine the detection limit of IC-
ELISA, 2 mg/ml HSA in PBS was spiked 
with 50–2000 pg/ml of AFB1-lys and 
then hydrolysed with 0.67 mg of pro-
teinase K (Amresco, Ohio) in 0.8 ml PBS 
at 37°C for ~ 17 h (ref. 13). Undigested 
proteins were removed using Sep-Pak 
cartridges (WAT051910, Waters Ltd, 
UK)13 or by precipitation with cold etha-
nol. This revealed 96 ± 11% recovery of 
the AFB1-lys in IC-ELISA (Table 1). 
Comparison of efficacy of albumin hy-
drolysis using cold ethanol precipitation 
procedure and Sep-Pak cartridges 
showed no significant differences, indi-
cating that low-cost ethanol precipitation 
approach is effective (Table 1). 
 Results of IC-ELISA were compared 
with HPLC using reversed-phase C18 
column (Shimadzu Liquid Chromatogra-
phy-LC-10AT VP) with a particle size 
5 μm diameter linked to a fluorescence 
detector (Shimadzu RF-10 AXL). Sol-
vent flow rate was 1 ml/min with mobile 
phase water : acetonitrile : methanol (70 : 
17 : 17). Fluorescence detection parame-
ters were set to excitation wavelength at 
360 nm and emission wavelength at 
440 nm. For each HPLC run, 20 μl of the 
hydrolysed HSA was injected into the 
column and fractions were collected at 
1 min interval. Two peaks were obtained, 
one major peak at 2.0 min corresponding 
to AFB1-lys and one minor peak at 
2.4 min (Figure 2), suggesting that 
AFB1-lys had a relative retention time of 
2 min. Each HPLC fraction was precipi-
tated in a vacuum evaporator, reconsti-
tuted with 250 μl of PBS and analysed in 
IC-ELISA. Results of IC-ELISA were 
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similar to HPLC results (SD ± 1.7 to 
17.8; Table 2) and there was no differ-
ence in the samples prepared by Sep-Pak 
cartridge or ethanol precipitation. 
 IC-ELISA was validated by testing 
250 blood samples that include 85 HBV 
positive samples from unidentified sub-
jects from the Apollo Health City,  
Hyderabad, and 165 blood samples col-
lected from ICRISAT campus, Hyderabad. 
Serum was separated by centrifugation at 
5000 rpm for 10 min and it was heat-
treated at 56°C for 45 min to inactivate 
any infectious HIV. Albumin fraction 
was extracted from 500 μl serum as de-
tailed in Chapot and Wild14, and its con-
centration was estimated by the Bradford 
method15. Two milligram albumin was 
hydrolysed with proteinase-K, precipi-
tated with ethanol and tested in  
IC-ELISA, as described above. AFB1-lys 
at a concentration between 2.5 and 
75 pg/mg albumin was detected in 12 
samples (Table 3). All the samples that 
were positive to AFB1-lys were from 
HBV-positive subjects, indicating a  
potential risk of HCC in 4.8% of the sub-
jects tested in the present study. This 
validation confirms the suitability of IC-
ELISA, which is simple, cost-effective 
and enables high-throughput analysis. 
 An earlier study in India using  
immunoperoxidase test detected AFB1  
deposits in 58% of 32 human liver  
biopsy samples from HCC cases, 15 of 
which were positive to HBV16. However, 
in the same study ELISA assay for AFB1 
biomarker was negative16. We speculate 
that negative results in ELISA could be 
linked to the time of assessment, as 
AFB1-lys biomarker is detectable for up
to 2 months from first exposure to AFB1. 
Nonetheless, earlier16 and current studies 
have demonstrated significant associa-
tion of AFB1 toxicity with HCC cases in 
India, and emphasize the need for wider 
surveillance to determine the AFB1-
exposed populations in the country. After  
thorough validation, IC-ELISA has the  
potential to serve as a tool for epidemi-
ological studies to identify vulnerable 
groups and implement appropriate inter-
ventions to minimize aflatoxin contami-
nation in diets of communities at high 
risk of AFB1 exposure17,18. Vulnerable 
individuals can be subjected to further 
specific tests to assess HCC risk and  
implement remedial treatments19. 
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Table 3. Estimation of AFB1-lys in human serum albumin by IC-ELISA 
AFB1-lys adduct concentration (pg/mg albumin)a Number of samples 
 
– b 232 
≤ 5   1 
6–25  13 
26–50   3 
51–75   1 
Total 250 
aAlbumin purified from serum fraction was hydrolysed with proteinase-K, purified with ethanol 
and tested in IC-ELISA. bOD equivalent to negative control. 
